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Antibody blockade of TNF-a reduces inflammation and scar-
ring in experimental crescentic glomerulonephritis.
Background. Tumor necrosis factor-a (TNF-a) is a proin-
flammatory cytokine produced by macrophages, and by renal
mesangial and tubular epithelial cells. It stimulates the release
of interleukin (IL)-1b , monocyte chemoattractant protein-1
(MCP-1), and transforming growth factor-b (TGF-b). Block-
ade of TNF-a is currently used clinically in several autoimmune
inflammatory diseases. We hypothesised that blocking TNF-a
with a monoclonal antibody would prevent inflammation and
renal fibrosis in crescentic glomerulonephritis.
Methods. Nephrotoxic nephritis was induced in Wistar Kyoto
(WKY) rats by intravenous injection of rabbit antirat glomeru-
lar basement membrane (GBM) nephrotoxic serum (NTS).
Anti-TNF-a monoclonal antibody or saline was given intraperi-
toneally three times per week in four protocols: experiment 1,
days 0 to 7; experiment 2, days 0 to 14 and days 4 to 14; experi-
ment 3, days 4 to 28; and experiment 4, days 14 to 28.
Results. In experiment 1, rats treated from disease induc-
tion had less glomerular fibrinoid necrosis and fewer glomeru-
lar macrophages at day 7. In experiment 2, rats treated from
day 0 or day 4 showed improved renal function, as judged by
serum creatinine, with a significant reduction in crescents. In
experiment 3, anti-TNF-a treatment significantly reduced urine
protein to creatinine ratio and urinary MCP-1 levels. Serum cre-
atinine was preserved at both day 14 and day 28. Tubulointer-
stitial inflammation, glomerular and tubulointerstitial scarring,
and markers of fibrosis [a-smooth muscle actin (a-SMA) and
type IV collagen] were significantly less in treated rats at day
28. In experiment 4, serum creatinine was higher and tubuloin-
terstitial scarring was less in delayed-treated animals.
Conclusion. Neutralization of endogenous TNF-a reduces
glomerular inflammation, crescent formation, and tubulointer-
stitial scarring, with preservation of renal function, in experi-
mental crescentic glomerulonephritis. TNF-a blockade is effec-
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tive even when introduced at the time of maximum glomerular
inflammation.
Tumor necrosis factor-a (TNF-a) is a proinflamma-
tory cytokine and mediator of many immune functions
[1], which is produced by a wide variety of cells, par-
ticularly monocytes, activated macrophages, and fibrob-
lasts. In the kidney it may be produced by intrinsic renal
cells, including mesangial cells and tubular epithelial cells,
in response to proinflammatory stimuli such as platelet-
derived growth factor (PDGF) and TNF-a itself. TNF-a
is present in a soluble form (17 kD), to which most of the
biologic effects are attributable, and also a membrane-
bound form (26 kD).
The TNF ligand receptor interaction is mediated via
two distinct cell surface receptors: TNFR1 (p55), which
predominates, and TNFR2 (p75). Both receptors act
synergistically for cell proliferation and maturation,
cytotoxicity, and antiviral activity. TNF-a ligation to
TNFR1 and TNFR2 can activate caspase 8 via in-
tracellular signaling events involving death domains,
or by activating c-Jun NH2-terminal kinase (JNK)
which is involved in phosphorylating the transcription
factor c-jun, promoting apoptosis [2]. Alternatively,
a TNF-induced survival signal can trigger a cascade
of intracellular events leading to the activation of
the transcription factor nuclear factor-jB (NF-jB),
which is involved in the suppression of apoptosis
and initiates gene transcription of many molecules
involved in acute and chronic inflammatory responses
[3]. These molecules include proinflammatory cytokines,
chemokines, and growth factors, such as interleukin
(IL)-1b , monocyte chemoattractant protein-1 (MCP-1),
transforming growth factor-b (TGF-b) and macrophage
migration inhibitory factor (MIF), which act to amplify
the inflammatory response. TNF blockade can inhibit
NF-jB activation, promoting increased apoptosis of
inflammatory cells, and reducing the inflammatory re-
sponse. Cell-type specific regulation can determine which
1812
Khan et al: Anti-TNF-a antibody in crescentic glomerulonephritis 1813
signaling pathway and transcription factors are recruited
to the TNF promoter. TNF-a can also be immunostimula-
tory, by inducing expression of major histocompatability
complex (MHC) class I and II molecules, and of
adhesion molecules [e.g., intercellular adhesion
molecule-1 (ICAM-1), vascular cell adhesion molecule-1
(VCAM-1) on antigen-presenting cells (APCs).
Overproduction of TNF-a plays a key role in acute
and chronic inflammatory diseases. It has been implicated
in the pathogenesis of several T-cell–mediated autoim-
mune diseases, including multiple sclerosis [4], rheuma-
toid arthritis [5], and inflammatory bowel disease [6].
Inhibition of endogenous TNF with monoclonal antibod-
ies or soluble TNF receptors interferes with the action of
the cytokine. This approach is currently used to treat in-
flammatory diseases such as Crohn’s disease and rheuma-
toid arthritis [7–9], and has been successful in modulating
disease progression.
There is considerable evidence that TNF-a plays a role
in glomerular inflammation and scarring [10]. In an ani-
mal model of minimal change nephropathy, TNF-a was
produced within glomeruli by mesangial cells, epithelial
cells, and infiltrating macrophages and monocytes [10,
11]. Systemic administration of TNF-a caused glomerular
damage in normal rabbits [12], and increased the degree
of glomerular injury in rats with nephrotoxic nephritis
[12, 13].
Neutralization of endogenous TNF-a in rats with cres-
centic nephritis using soluble TNFR p55, a soluble trun-
cated fragment of the extracellular domain of TNFR1,
prevented acute glomerular inflammation and crescent
formation [14, 15]. In a rat model of experimental cres-
centic nephritis, MIF was up-regulated in renal intrin-
sic cells and infiltrating macrophages. When treated with
TNF binding protein, a dimeric form of the soluble recep-
tor, serum levels of MIF decreased, along with a reduc-
tion in renal injury and interstitial fibrosis, indicating that
TNF-a induces MIF expression and that together they
enhance renal inflammation [16].
Experiments using TNF-a−/− knockout mice have
also demonstrated a reduction in severity of crescen-
tic nephritis induced by antiglomerular basement anti-
body [17]. These TNF-a−/− animals have also been used
to create chimeric mice, to distinguish the role of bone
marrow–derived versus intrinsic renal cell TNF-a [18].
These studies suggest that intrinsic renal cells are the ma-
jor contributor to TNF-mediated injury.
The role of TNF-a in the pathophysiology of renal
fibrosis has been examined in a mouse model of unilat-
eral ureteric obstruction (UUO) [19, 20] in which individ-
ual TNF-a receptors, TNFR1 or TNFR2, were knocked
out. Mice deficient in either receptor, especially TNFR1,
demonstrated reductions in interstitial volume, myofi-
broblast differentiation, collagen deposition, and NF-jB
activation, compared to the wild-type.
The only previous study using anti-TNF-a antibod-
ies in a rat model of nephrotoxic nephritis was a 24-
hour experiment, using a polyclonal anti-TNF antibody,
which reduced proteinuria and glomerular accumulation
of neutrophils [21]. We hypothesized that blocking TNF-
a with a monoclonal antibody, at either acute or chronic
stages of disease, would be effective in preventing and
treating experimental crescentic glomerulonephritis. The
model we have used is induced in Wistar Kyoto (WKY)
rats by a single intravenous injection of rabbit antirat
glomerular basement membrane (GBM) serum. This ini-
tiates a vigorous inflammatory response, characterized
by up-regulation of proinflammatory cytokines and adhe-
sion molecules, together with recruitment of leukocytes
into the glomeruli. The cell influx is underway by day
1 of disease and is predominantly monocytic. Glomeru-
lar leukocyte counts peak at day 3 or 4. Glomerular fib-
rinoid necrosis and crescent formation begin by day 7,
and peak around day 14. Tubulointerstitial inflammation
accompanies crescent formation and is followed by in-
creasing interstitial fibrosis, tubular damage and progres-
sive glomerulosclerosis [22]. Creatinine clearance starts
to fall and serum creatinine starts to rise by day 14 of
nephrotoxic nephritis. Animals develop end-stage renal
failure by week 5 or 6.
In the present study we have examined the effect of a
blocking antibody to TNF-a, administered either during
the phase of acute inflammation or during the scarring
phase of nephrotoxic nephritis. Our results clearly show
that inhibition of TNF-a reduces both acute glomerular
inflammation and glomerular and interstitial fibrosis, and
prevents the development of renal failure.
METHODS
Animals
Male WKY rats aged between 6 and 8 weeks (weight
200 to 250 g) were purchased from Charles River Labora-
tories (Margate, UK) and had free access to standard lab-
oratory diet and water. All procedures were performed in
accordance with the United Kingdom Animals (Scientific
Procedures) Act.
Antibodies
A blocking IgG2a monoclonal antibody to rat TNF-
a (C432) (Centocor, Philadelphia, PA, USA) was used
in all experiments. In prior pilot experiments and in our
previous studies [14, 23, 24], an isotype matched control
monoclonal antibody showed no effect on renal injury in
comparison to saline, and therefore saline injections were
used as a control in the present study.
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Nephrotoxic nephritis
Nephrotoxic serum was prepared in rabbits by stan-
dard methods [25]. Briefly, rat glomeruli were isolated,
sonicated, and lyophilized to provide a rat GBM prepa-
ration with <5% tubular contamination. Rabbits were
immunized with rat GBM in Complete Freund’s Adju-
vant (CFA), then boosted at monthly intervals with GBM
in Incomplete Freund’s Adjuvant (IFA), until high titer
anti-GBM antiserum was obtained at test bleeds. Nephro-
toxic nephritis was induced in male WKY rats by in-
travenous injection of 0.1 mL of nephrotoxic serum, as
previously described [22].
Assessment of renal disease
Urine was collected by placing rats into metabolic cages
for 24 hours, at weekly intervals, with free access to food
and water. Proteinuria was determined by the sulphosali-
cylic acid method [26]. Tail artery bleeds were performed
at weekly intervals, under light anesthesia using isoflu-
rane, to allow determination of serum creatinine using
an Olympus AU600 analyser (Olympus, Eastleigh, UK).
Urinary creatinine concentration was measured to per-
mit calculation of urine protein to creatinine ratio. Rats
were killed under isoflurane anesthesia, and blood was
collected from the abdominal aorta.
Renal histology
At sacrifice, one portion of kidney was fixed in 10%
formal saline and embedded in paraffin. Kidney tissue
was also snap frozen in isopentane, immersed in liquid
nitrogen, and stored at −70◦C. Paraffin sections were
stained with hematoxylin and eosin, and periodic acid-
Schiff (PAS), and examined in a blinded fashion for
glomerular scarring, tubular damage, and interstitial scar-
ring. The percentage of glomeruli containing crescents
was determined by examining 100 consecutive glomeruli
per section. Glomerular scarring at day 28 was assessed
in hematoxylin and eosin sections by scoring the number
of glomerular quadrants containing scars.
Immunohistochemistry and immunofluorescence
The monoclonal antibodies used were specific for
rat monocytes/macrophages (ED1) (Serotec, Oxford,
UK); CD8 cells (OX8) (Serotec); ED(A) fibronectin
[ED(A)FN] (IST-9) (Harlan Sera-Lab, Loughborough,
UK); type IV collagen (Southern Biotechnology, Birm-
ingham, AL, USA); inducible nitric oxide synthase
(iNOS) (clone 6) (BD Transduction Laboratories,
Oxford, UK); a-smooth muscle actin (a-SMA) (IA4);
goat antirabbit IgG fluorescein isothiocyanate (FITC);
and rabbit antirat IgG FITC (Sigma-Aldrich, Poole, UK).
For direct immunofluorescence for rabbit and rat IgG,
frozen sections were fixed in acetone and blocked with
20% normal goat or rabbit serum, respectively, then in-
cubated for 2 hours with FITC-conjugated monoclonal
antibody to rabbit IgG (1:80) or rat IgG (1:20). For
ED(A)FN staining, frozen sections were fixed in ace-
tone, and endogenous peroxidase blocked using 0.03%
hydrogen peroxide in methanol. Sections were blocked
with 20% normal rabbit serum and incubated overnight
at 4◦C with monoclonal antibody to ED(A)FN (1:1000).
Sections were washed and incubated with a rabbit anti-
mouse biotinylated secondary antibody (Dako, Glostrup,
Denmark). Bound antibody was detected using the
avidin-biotin complex (ABC) method (Dako), with
the chromogenic substrate 3,3′-diaminobenzidine (DAB)
(Dako). Sections were counterstained with hematoxylin
and mounted.
The other antibodies were used on paraffin sections at
the following dilutions: ED1, 1:500; OX8, 1:200; iNOS,
1:50; a-SMA, 1:1000; and type IV collagen, 1:1000.
Antigen retrieval was carried out by heating paraffin-
embedded sections in 10% citrate buffer in a microwave
oven, three times, each for 5 minutes. Sections were then
treated as for frozen tissue, with blocking of endogenous
peroxidase, blocking with 20% normal rabbit serum, and
incubation overnight with primary monoclonal antibody
at 4◦C. Sections were washed and then incubated with
biotinylated rabbit antimouse antibody for ED1, OX8,
and a-SMA, or biotinylated rabbit antigoat antibody for
type IV collagen. Bound antibody was detected using
ABC followed by DAB. Sections were counterstained
with hematoxylin and mounted. ED1-, OX8-, and iNOS-
positive cells were counted in 25 consecutive glomeruli
or interstitial areas in randomized sections.
Computer-aided image analysis of immunofluorescence
and immunohistochemistry
To quantify glomerular and interstitial fibrosis, im-
munoperoxidase and immunofluorescence kidney sec-
tions were examined under ×20 magnification, using an
Olympus BX40 microscope (Olympus Optical, London,
UK) mounted with a Photonic Science Color Coolview
digital camera (Photonic Science, East Sussex, UK). Dig-
ital images were captured and analyzed using Image-Pro
Plus software (Media Cybernetics, Silver Spring, MD,
USA), and color segmentation was performed for each
slide individually, defining pixels that contained appropri-
ate coloration. For each slide, 20 consecutive glomeruli or
cortical areas were defined as an “area of interest,” and
the percentage of each cross-sectional area stained with
the defined color was calculated. The final value for each
slide was derived as the mean percentage area stained
from 20 areas.
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Circulating rat antirabbit Ig measurement
A direct enzyme-linked immunosorbent assay
(ELISA) was performed to quantify the levels of
circulating rat antirabbit Ig levels in serum samples.
A 96-well ELISA plate was coated with rabbit IgG
in carbonate buffer antibody (Sigma-Aldrich) at 100
lg/mL, at 4◦C overnight. The plate was blocked with a
blocking buffer [phosphate-buffered saline (PBS), 1%
bovine serum albumin (BSA), and 0.1% Tween 20] for
1 hour at 37◦C. Serum samples from experimental rats
were diluted 1:200 in PBS, 1% BSA, and 0.1% Tween
20 and were incubated for 1 hour at 37◦C. The detec-
tion antibody, alkaline phosphatase-conjugated rabbit
antirat Ig (Sigma-Aldrich) diluted 1:1000, was added to
wells and incubated for 1 hour at 37◦C. The substrate
p-nitrophenyl phosphate (p-NPP) (Sigma-Aldrich)
dissolved in carbonate buffer was added to the plate
then incubated for 30 minutes at room temperature.
The plate was read at 450 nm. Amounts of circulating
rat antirabbit Ig were expressed as optical density (OD)
units.
Urinary and serum MCP-1 measurement
A direct ELISA was performed to quantify the amount
of MCP-1 in urine and serum samples. A 96-well ELISA
plate was coated with a capture antibody, antirat MCP-
1 (C4) (BD Pharmingen, Oxford, UK) at 1 lg/mL, at
room temperature overnight. The plate was blocked with
a blocking buffer (PBS, 1% BSA, 5% sucrose, and 0.05%
NaN3) for 1 hour at room temperature. Recombinant
rat MCP-1 standards (Peprotech EC Ltd., London, UK)
were serially diluted from 1 lg/mL to 2 ng/mL, and ex-
perimental urine (1:20) and serum (1:50) samples were
incubated for 2 hours at room temperature. The detec-
tion antibody, biotinylated antirat MCP-1 (B4), (Pepro-
tech EC Ltd.) at 0.3 lg/mL, was added to wells and
incubated for 2 hours at room temperature. Streptavidin
horseradish peroxidase (HRP) (Zymed, San Francisco,
CA, USA) diluted 1:10,000, was then incubated for 20
minutes, followed by substrate reagent (R&D Systems,
Minneapolis, MN, USA) for 20 minutes. One mole per
liter H2SO4 was used to stop the reaction and the plate
was read at 450 nm. Amounts of MCP-1 were expressed
as ng/mmol creatinine.
Experimental design
Experiment 1. This was designed to determine an ef-
fective dose of anti-TNF-a monoclonal antibody for pre-
vention of inflammation at an early stage of nephrotoxic
nephritis, from day 0 to day 7. The first dose was admin-
istered 2 hours before the induction of disease. Nephro-
toxic nephritis was induced in 12 WKY rats. Four were
treated with anti-TNF-a monoclonal antibody, 1 mg/rat
intraperitoneally on alternate days; four were treated
with 4 mg/rat; and four received normal saline as a con-
trol. All rats were killed at day 7.
Experiment 2. This was designed to study the preven-
tive and therapeutic effects of anti-TNF-a monoclonal
antibody with continued treatment between days 0 and
14. Treatment was started either at day 0 (experiment 2a)
or at day 4 (experiment 2b), by which time there is es-
tablished glomerular inflammation. Nephrotoxic nephri-
tis was induced in 18 WKY rats. Six rats were treated
with anti-TNF-a monoclonal antibody, 4 mg/rat intraperi-
toneally on alternate days from day 0; six rats were treated
with anti-TNF-a monoclonal antibody, 4 mg/rat intraperi-
toneally on alternate days from day 4; and six received
normal saline. All rats were killed at day 14.
Experiment 3. This was designed to study the pro-
longed therapeutic effect of anti-TNF-a monoclonal an-
tibody on renal function, and glomerular and interstitial
scarring, with treatment from day 4 to day 28. Nephro-
toxic nephritis was induced in 12 WKY rats. At day 4,
six rats were treated with anti-TNF-a monoclonal anti-
body, 4 mg/rat intraperitoneally on alternate days; and
six received normal saline. All rats were killed at day 28.
Experiment 4. This was designed to study the effect
of late treatment with anti-TNF-a monoclonal antibody,
started on day 14 when there is severe glomerulonephritis
with maximal crescent formation. Nephrotoxic nephri-
tis was induced in 10 rats. At day 14, five rats were
treated with anti-TNF-a monoclonal antibody, 4 mg/rat
intraperitoneally on alternate days; and five received nor-
mal saline. All rats were killed at day 28.
Statistics
Data are expressed as mean ± SEM. Repeated mea-
sure comparisons between test and control groups for in
vivo blocking monoclonal antiboy experiments were by a
two-way analysis of variance (ANOVA) test. Differences
were considered significant if P < 0.05. Statistical calcu-
lations were performed using Prism software (GraphPad
Prism Software Inc., San Diego, CA, USA).
RESULTS
Effect of anti-TNF-a monoclonal antibody in acute
nephrotoxic nephritis
In experiment 1, rats were treated from day 0 to
day 7 with anti-TNF-a monoclonal antibody at 1 mg/rat
or 4 mg/rat on alternate days, to determine an effec-
tive dose for prevention. Rats treated with either 1 mg
or 4 mg of anti-TNF-a monoclonal antibody showed
reduced glomerular fibrinoid necrosis compared to
control rats (1 mg 1.33 ± 0.18; 4 mg 0.89 ± 0.08; and
control 1.58 ± 0.09 glomerular fibrinoid necrosis score),
but this only reached significance at the higher dose
(4 mg dose) (P < 0.05). There were fewer glomerular
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Fig. 1. Experiment 2. Renal function and percentage crescents in in-
dividual rats treated with anti-tumor necrosis factor-a (TNF-a) mono-
clonal antibody from day 0 or day 4 until day 14. (A) Serum creatinine
was lower in animals treated from either day 0 (∗P < 0.05) or from day
4 (∗P < 0.05) compared with controls. (B) Percentage of crescents was
lower in animals treated from either day 0 (∗∗P < 0.01) or day 4 (∗∗P <
0.01) compared with controls. Treatment began at day 0 (), day 4 (),
and control ().
macrophages in both treated groups than in the controls
(1 mg 13.8 ± 0.7; 4 mg 13.5 ± 1.4; and control 23.5 ±
1.8 macrophages/glomerulus) (P < 0.05). There was no
effect on the number of infiltrating CD8-positive cells
(1 mg 2.2 ± 0.33; 4 mg 1.8 ± 0.56; and control 1.3 ±
0.61 CD8+ cells/glomerulus), urine protein to creatinine
ratio (1 mg 0.95 ± 0.37; 4 mg 0.97 ± 0.24; and control,
0.98 ± 0.35 mg/lmol), or serum creatinine (1 mg 48.5 ±
3.2; 4 mg 44.5 ± 1.0; and control 53.8 ± 2.7 lmol/L). The
dose of 4 mg/rat on alternate days was used in subsequent
experiments.
In experiment 2, rats were treated from day 0 to day 14
or from day 4 to day 14 at the established dose of 4 mg/rat
on alternate days. Renal function, as judged by serum cre-
atinine, was better in rats treated with anti-TNF-a mon-
oclonal antibody from the time of induction of disease
(70.5 ± 5.7 lmol/L) (P < 0.05) or from day 4 (69.2 ±
4.5 lmol/L) (P < 0.05) compared with controls (102.3 ±
9.4 lmol/L) at day 14 (Fig. 1A). There was, however, no
significant difference in urine protein to creatinine ratio
at day 14, between animals treated from day 0 (0.95 ±
0.10 mg/lmol) or from day 4 (1.09 ± 0.10 mg/lmol) com-
pared with controls (1.36 ± 0.26 mg/lmol). At day 14 in
this model, around 90% of glomeruli contained cellular
crescents [22]. There was a significant reduction in cres-
cents (P < 0.01) in animals treated from either day 0 or
day 4 (days 0 to 14 66.7 ± 5.2%; days 4 to 14 60.3 ± 3.1%;
and control 91.6 ± 2.0%), (Fig. 1B). Cellular infiltration
of macrophages (day 0 27.3 ± 2.5; day 4 26.2 ± 3.5; and
control 24.2 ± 3.8 macrophages/glomerulus) and CD8-
positive cells (day 0 0.85 ± 0.3; day 4 1.19 ± 0.3; and con-
trol 0.77 ± 0.2 CD8-positive cells/glomerulus) into the
glomeruli was not different between groups. However,
the number of iNOS-positive cells was increased in rats
treated from day 0 and from day 4 compared to controls:
day 0 6.2 ± 1.2 (P< 0.05); day 4 4.3 ± 1.4 (P = NS); and
control 1.0 ± 0.32 iNOS-positive cells/glomerulus.
Effect of anti-TNF-a monoclonal antibody on
progression of glomerulonephritis
In experiment 3, rats were treated from days 4 to 28.
Assessment of urine protein to creatinine ratio demon-
strated a reduction in the treated group at day 14 (treated
1.30 ± 0.23 and control 4.19 ± 0.69 mg/lmol) (P < 0.01),
but not at day 28 (treated 1.11 ± 0.14 and control 1.48 ±
0.19 mg/lmol) (Fig. 2A). Serum creatinine at both day 14
(treated 58.2 ± 3.8 lmol/L and control 74.8 ± 6.1 lmol/L)
(P < 0.05) and at day 28 (treated 48.5 ± 1.6lmol/L and
control 96.2 ± 16.7 lmol/L) (P < 0.001) was significantly
less in treated animals (Fig. 2B).
Glomerular and tubulointerstitial scarring were scored
and ranked respectively in randomized hematoxylin and
eosin–stained sections. At day 28, the mean glomerular
quadrant scar score was significantly less in the treated
animals compared to the controls (treated 0.5 and con-
trol 2.2) (P < 0.01). The treated group also showed sig-
nificantly less tubulointerstitial scarring than the controls
(treated 0.6 and control 2.4) (P < 0.01) (Fig. 3).
Quantitative assessment of fibrosis was performed us-
ing an immunohistochemical stain for type IV collagen.
There was a significant decrease in the percentage cor-
tical area stained at day 28 in treated animals (treated
1.9 ± 1.1% and control 9.3 ± 2.2%) (P < 0.05) (Fig. 4). a-
SMA is an actin isoform expressed in smooth muscle cells,
fibroblasts, and mesangial cells undergoing myofibrob-
lastic transformation. This phenotype is associated with
matrix synthesis, and therefore acts as a marker of future
fibrosis. There was a significant decrease in glomerular
a-SMA at day 28 in treated animals (treated 2.3 ± 0.6%
and control 11.5 ± 2.3%) (P < 0.01). Another marker
of renal fibrosis is the ED(A) splice variant domain of
fibronectin (FN). Quantitation of glomerular staining for
ED(A)FN showed that there was reduced expression in
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Fig. 2. Experiment 3. Renal function in rats treated with anti-tumor
necrosis factor-a (TNF-a) monoclonal antibody from day 4 until day
28. (A) Urinary protein to creatinine ratio was lower in animals treated
from day 4 until day 28, at day 14 (∗∗P < 0.01) compared with controls.
(B) Serum creatinine was lower in animals treated from day 4 until day
28, at day 14 (∗∗P < 0.01) and day 28 (∗∗∗P < 0.001) compared with
controls. Anti-TNF-a monoclonal antibody () and control ().
the treated animals compared to controls (treated 12.3 ±
2.5% and control 19.6 ± 3.2%) (P= 0.09). Anti-TNF-a
monoclonal antibody treatment did not have an effect on
glomerular infiltration by macrophages (treated 3.6 ± 0.7
and control 5.0 ± 0.7 macrophages/glomerulus) or CD8-
positive cells. However, tubulointerstitial counts showed
significantly lower numbers of interstitial macrophages
in the treatment group (treated 5.3 ± 1.2 and control
20.5 ± 1.9 macrophages/interstitial area) (P < 0.01).
Urinary and serum MCP-1 levels were measured using
a direct ELISA. Animals treated with anti-TNF-a mon-
oclonal antibody had significantly reduced amounts of
MCP-1 in their urine in comparison to control animals
at day 14 (treated 1.6 ± 0.23 and control 4.4 ± 1.0 ng
MCP-1/mmol creatinine) (P < 0.05) and 28 (treated
0.7 ± 0.14 and control 3.5 ± 0.89 ng MCP-1/mmol cre-
atinine) (P < 0.01). There was no significant difference
in serum MCP-1 levels at day 28.
Rabbit and rat IgG deposition in the glomeruli were
quantitated by direct immunofluorescence, and were sim-
ilar in both groups. In addition, circulating levels of rat
antirabbit Ig in the serum were quantitated by ELISA,
and were similar in both groups (treated 2.4 ± 0.12 and
control 1.8 ± 0.22 OD units). This indicates that blockade
of TNF-a did not affect glomerular deposition of admin-
istered rabbit IgG, or the animals’ immune response (rat
IgG) to the planted rabbit immunoglobulin.
Effect of delayed treatment with anti-TNF-a monoclonal
antibody in glomerulonephritis
In experiment 4, rats were treated from day 14 to day
28 with anti-TNF-a monoclonal antibody. Treatment was
started at the time of maximal crescent formation in or-
der to mimic the clinical situation in which patients often
present with severe disease.
There was no difference between the groups in urine
protein to creatinine ratio at day 28 (treated 2.09 ± 0.18
and control 1.64 ± 0.11 mg/lmol). After 2 weeks of treat-
ment, at day 28, treated animals had a lower level of serum
creatinine than controls (treated 85.0 ± 3.2 lmol/L and
control 134.0 ± 12.5 lmol/L) (P < 0.05) (Fig. 5). This was
associated with reduced tubulointerstitial scarring in rats
killed at day 28. Semiquantitative assessment by rank-
ing showed a significant reduction in interstitial scarring
in treated rats (P < 0.05). Quantitation of glomerular
inflammatory cells showed no significant difference in
numbers of glomerular macrophages (treated 3.2 ± 1.0
and control 3.3 ± 0.4 macrophages/glomerulus) or CD8-
positive cells between treated and control groups. Rabbit
and rat IgG deposition in the glomeruli were similar in
both groups. Levels of circulating rat antirabbit Ig were
also similar in both groups (treated 2.0 ± 0.16 and control
1.7 ± 0.11 OD units).
DISCUSSION
Blockade of TNF-a is increasingly used in predom-
inantly T-cell–mediated autoimmune diseases such as
Crohn’s disease and rheumatoid arthritis [7, 8]. Treatment
with anti-TNF antibodies in these diseases has proven to
be effective in the majority of patients. The success of
TNF inhibition has encouraged research in other chronic
inflammatory diseases. We hypothesized that blocking
TNF-a with a monoclonal antibody would reduce both
inflammation and fibrosis in crescentic glomerulonephri-
tis.
Anti-TNF-a therapy was initially investigated in the
acute phase of the nephrotoxic nephritis model, as this
is when inflammation is predominant. Anti-TNF-a an-
tibody was effective in reducing fibrinoid necrosis and
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Fig. 3. Experiment 3. Histology of kidney sections from rats treated with anti-tumor necrosis factor-a (TNF-a) monoclonal antibody from day 4
until day 28. (A) Histology from a control animal showing marked glomerular scarring with fibrous crescents, tubulointerstitial scarring with tubular
atrophy, and tubulointerstitial inflammation (hematoxylin and eosin ×10). (B) Histology from a treated animal showing reduced glomerular and
tubulointerstitial scarring, less tubular atrophy, and reduced interstitial inflammation compared with control (hematoxylin and eosin ×10).
Fig. 4. Experiment 3. Immunohistochemistry for type IV collagen in kidneys from rats treated with anti-tumor necrosis factor-a (TNF-a) mono-
clonal antibody from day 4 until day 28. (A) Cortical type IV collagen immunohistochemistry from a control animal showing marked deposition
(×20). (B) Cortical type IV collagen immunohistochemistry from an anti-TNF-a monoclonal antibody–treated animal showing reduced deposition
compared with control (×20).
glomerular macrophage infiltration when given from day
0 to day 7. Effectiveness was also demonstrated when an-
tibody was given from day 0 to day 14, or from day 4 to day
14, with a reduction in glomerular crescents and preserva-
tion of renal function. Of note, the second of these studies
showed that treatment was effective even when started at
day 4, when there is maximum glomerular macrophage
infiltration [22].
These experiments were extended to investigate
whether suppression of the initial glomerular inflamma-
tion would lead to a sustained improvement in renal func-
tion and reduction in scarring. Treatment was begun at
day 4 and continued until day 28, at which time kid-
neys in untreated animals show considerable glomeru-
lar and tubulointerstitial scarring. Beneficial effects were
sustained in later stages of the disease, as shown by the
finding that renal function was preserved, and markers
of fibrosis, including type IV collagen and a-SMA, were
significantly reduced at day 28. Urinary levels of the
chemokine MCP-1 were also significantly reduced. When
treatment was delayed to day 14 of disease, at which time
there is severe glomerulonephritis with maximal crescent
formation, blockade of TNF-a was still effective. There
was preservation of renal function and reduction in inter-
stitial scarring, but no effect on glomerular scarring.
Previous studies in rodent models of crescentic
glomerulonephritis have involved the blockade of TNF-
a with soluble TNFR p55 or TNF binding protein, which
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Fig. 5. Experiment 4. Renal function in rats treated with anti-tumor
necrosis factor-a (TNF-a) monoclonal antibody from day 14 until day
28. Serum creatinine was lower in treated animals at day 28 (∗P <
0.05) compared with controls. Anti-TNF-a monoclonal antibody ()
and control ().
bind circulating TNF [14–16]. It is possible that the ef-
fects of soluble receptors may not be the same as mon-
oclonal antibodies. Antibody treatment will bind both
soluble and membrane-bound TNF, while the soluble re-
ceptor binds soluble TNF alone. In addition, binding of
membrane bound TNF by antibody therapy may promote
antibody-dependent cell cytotoxicity and apoptosis of ac-
tivated effector T cells and macrophages, which may be an
important mechanism of action. In support of this differ-
ence, in Crohn’s disease the chimeric anti-TNF antibody,
infliximab, shows good efficacy in treatment; however, the
soluble TNF receptor, etanercept, has not proven to be so
effective [27, 28]. Previous experimental studies of TNF
blockade in glomerulonephritis have another limitation,
as they were short term [14, 15] and thus less directly rel-
evant to progression of disease in patients. Our present
work addresses the role of TNF-a in long-term studies,
by investigating the treatment and prevention of nephro-
toxic nephritis at more clinically relevant stages.
TNF-a is paramount in the inflammatory response, as
it stimulates a cascade of events, including the produc-
tion of other proinflammatory cytokines (e.g., IL-1, IL-6,
and MIF), chemokines (e.g., MCP-1), and growth fac-
tors (e.g., TGF-b). It has long been considered that the
source of TNF-a in renal inflammation was infiltrating
macrophages; however, recent studies using TNF-a−/−
chimeric mice have shown that production from intrinsic
renal cells is also important [18]. TNF-a synthesized by
mesangial cells and podocytes acts to enhance inflamma-
tory cell recruitment, stimulate mesangial cell production
of TGF-b , and promote glomerular fibrin deposition by
inducing release of tissue factor.
There is mounting evidence that TNF-a is also con-
tributory to the development of fibrosis. TNF-a is widely
accepted to play a major role in mediating interstitial pul-
monary fibrosis. In a model of bleomycin-induced lung
disease, anti-TNF-a treatment has been shown to be ef-
fective in reducing pulmonary fibrosis, and in lowering
MCP-1 and TGF-b mRNA levels in the lung [29]. In
another study, using mice deficient in both TNFR1 and
TNFR2, exposure to asbestos fibers increased levels of
TNF-a gene and protein expression; however, these mice
were protected from developing fibroproliferative lesions
by a lack of receptor signaling [30]. These studies demon-
strate a fibrogenic role for TNF-a, by inducing cytokines
and profibrotic factors that amplify the inflammatory re-
sponse and progression to fibrosis.
During disease progression in glomerulonephritis, cel-
lular infiltration into the kidney allows interaction of in-
flammatory cells with glomerular cells and fibroblasts,
thus stimulating the synthesis of extracellular matrix and
leading to glomerular and tubulointerstitial scarring. The
development of proteinuria activates proximal tubular
epithelial cell NF-jB and induces secretion of MCP-1 into
the interstitium from an early time point in experimental
and human glomerulonephritis [31, 32]. MCP-1 can also
be produced by renal fibroblasts, as demonstrated by in
vitro coculture experiments [33]. An overall increase in
MCP-1 subsequently results in the recruitment of circu-
lating mononuclear cells to within the tubulointerstitial
area. In the present study, treatment with anti-TNF-a an-
tibody from day 4 to day 28, reduced proteinuria, together
with a reduction in tubulointerstitial macrophages and
urinary MCP-1 levels. This reduction in urinary MCP-1,
in the presence of similar serum levels, may reflect re-
duced renal production of MCP-1, which could be a po-
tential mechanism in preventing tubulointerstitial fibrosis
in glomerulonephritis.
Our results support the proposition that TNF-a is cen-
trally involved in the pathogenesis of glomerulonephri-
tis, and is thus a key therapeutic target. Neutralization
of endogenous TNF-a with anti-TNF-a monoclonal an-
tibody in this model of nephrotoxic nephritis reduces
glomerular inflammation, crescent formation, and inter-
stitial scarring, and prevents renal failure. These studies
suggest that TNF-a is important in both the early inflam-
matory phase and the later scarring phase of the disease. It
seems likely that the effects of TNF blockade in glomeru-
lonephritis are at least partly due to the reduced activity
of downstream mediators, such as MCP-1. It remains un-
clear whether TNF-a blockade reduces renal fibrosis pre-
dominantly by preventing inflammation, or whether it is
affecting both phases of the disease by separate mech-
anisms. Our delayed studies suggest, but do not prove,
a direct effect on renal scarring, as previously observed
in TNFR knockout mice. Regardless of the exact mech-
anism, our work clearly demonstrates that blockade of
TNF-a is effective in experimental crescentic glomeru-
lonephritis. Preliminary studies suggest a benefit of this
approach in patients with glomerulonephritis due to
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systemic vasculitis [34], and randomized clinical trials are
clearly needed.
Reprint requests to Charles D. Pusey, Renal Section, Faculty of
Medicine, Imperial College London, Hammersmith Campus, London,
W12 0NN, UK.
E-mail: c.pusey@imperial.ac.uk
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